Alnylam Pharmaceuticals Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
710 / 1361
Position in country
10365 / 14179
Return on Assets, %
-12.7
-40.3
Net income margin, %
-31.4
-180
EBITDA margin, %
-23.5
-168.2
Intangible assets and goodwill, %
0
0.2
Revenue CAGR 3Y, %
54.8
12.5
Total Equity change 1Y, %
39.4
-9
Revenue Y, % chg
76.2
0
P/BV
-84.7
1.8
P/S
10.2
10.3
EV/S
9.4
7.5
EV/EBITDA
-98.7
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
48.8
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Madrigal Pharmaceuticals Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
18701.1
Ticker
ALNY.O
ISIN
US02043Q1076
IPO date
2004-05-28
Availability on Russian exchanges
Yes
Reporting for
2024-02-15
Date fact. publication of reports
2023-12-31
Company Description
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: